The KIF6 gene encodes a kinesin.

To time, the advantages of statin therapy for KIF6 carriers has only been studied with atorvastatin and pravastatin therapy.. Celera receives patent on KIF6 gene variant Celera Company today announced that the United States Patent and Trademark Workplace has issued USA Patent 7,799,530 relating to methods of determining coronary attack risk by detecting the KIF6 gene variant and reduction of such increased risk by statin therapy. The KIF6 gene encodes a kinesin, a known member of a family of proteins involved in microtubule-mediated intracellular transport. Previous research has shown that variant of the KIF6 gene is associated with up to a 55 percent increased risk of primary and recurrent cardiovascular system disease occasions in the placebo hands of pravastatin clinical trials, and that increased risk was decreased with statin therapy significantly.In some full cases, the first bracing eliminates the necessity for any braces down the road. The American Association of Orthodontists recommends examining kids by age 7 to find if they will require orthodontic care. It is possible that failure to take action will result in malformation of the jaw and feasible overcrowding of the adult tooth. This early intervention will result in a reduction in aggressive action later most likely, like extraction.